dev.synapcell.com Open in urlscan Pro
46.255.162.123  Public Scan

Form analysis
1 forms found in the DOM

GET https://dev.synapcell.com/

<form class="search-form" role="search" method="get" action="https://dev.synapcell.com/">
  <fieldset class="semantic">
    <input placeholder="Search …" type="search" name="s" id="s1" data-swplive="true" value="">
    <input type="submit" id="searchsubmit1" title="Search" value="Search">
  </fieldset>
</form>

Text Content

SynapCell

 * ABOUT
   * WHO WE ARE
   * BACK TRANSLATE
   * PARTNERING WITH US
   * CAREERS
   * RESOURCES
 * BIOMARKERS
   * WHY EEG BIOMARKERS?
   * WHAT IS CUE?
   * WHICH BIOMARKER FOR MY RESEARCH?
 * SERVICES
   * EPILEPSY
     * Epileptic disorders
     * Focal Epilepsy
     * Generalized epilepsy
     * Essential Tremor
   * PARKINSON'S DISEASE
     * Parkinson's disease
     * Prodromal Parkinson's disease
     * Late-onset Parkinson's disease
     * L-DOPA induced Dyskinesia
   * EXPLORATORY
     * Translational expertise
     * Therapeutic exploration
     * Biomarker identification
     * Open innovation
     * Data analysis
     * Model Phenotyping
 * TESTIMONIALS
 * OPEN INNOVATION
   * OPEN INNOVATION
   * INNOVATIONS PIPELINE
 * CAPABILITIES
   * WHAT WE CAN DO
   * FAQ
 * CONTACT

Search



PREDICTIVE TESTING

for drugs targeting Central Nervous System disorders

Play Video



BROWSE OUR PROGRAMS


EPILEPTIC


DISORDERS

AED efficacy evaluation using predictive
EEG biomarkers and models of epilepsy

Learn more


PARKINSON’S


DISEASE

Unlock the potential of your drug on prodromal,
late-onset phases of PD or on L-DOPA induced Dyskinesia

Learn more


EXPLORATORY


PROGRAMS

Together let’s push the boundaries
of translational Neuroscience

Learn more


LATEST NEWS &EVENTS



LATEST NEWS EVENTS




SYNAPCELL AND THE UNIVERSITY OF UTAH CELEBRATE THEIR 10 YEAR ANNIVERSARY OF
COLLABORATION ON ANTI SEIZURE MEDICATIONS


EILAT XVII


ADPD 2024


ASENT 2024 – AMERICAN SOCIETY FOR EXPERIMENTAL NEUROTHERAPEUTICS


CNS THERAPEUTICS XCHANGE 2023 IN ZURICH


SOCIETY FOR NEUROSCIENCE IN WASHINGTON, NOVEMBER 2023


SYNAPCELL PARTICIPATES TO ECNP CONGRESS AND BIOJAPAN YOKOHAMA


CNS THERAPEUTICS XCHANGE 2023 WEST COAST


EPILEPSY THERAPIES & DIAGNOSTICS DEVELOPMENT (ETDD)


CNS THERAPEUTICS XCHANGE 2023 EAST COAST AND ESSENTIAL TREMOR CONGRESS


SYNAPCELL SPONSOR OF ASENT 2023


SOCIETY FOR NEUROSCIENCE 2022 – SAN DIEGO


CNS THERAPEUTICS XCHANGE 2022 – EUROPE ZÜRICH


BIOJAPAN 2022


CNS THERAPEUTICS XCHANGE 2022 – US WEST COAST


SYNAPCELL SHOWCASED INTO GEN MAGAZINE


NEUROSCIENCE EVENTS IN PARIS, JULY 2022


SYNAPCELL’S EXPERTS HIT THE WEST COAST ROAD ! [JUNE 2022]


EILAT XVI CONFERENCE ON NEW ANTIEPILEPTIC DRUGS & DEVICES


ADPD 2022: EEG BIOMARKERS USED TO EVALUATE ANTI-DYSKINETIC EFFECT OF DRUGS IN
PARKINSON’S DISEASE


ASENT 2022


SYNAPCELL AND RESERVOIR NEUROSCIENCE ANNOUNCE COLLABORATION FOR DEVELOPMENT OF
TREATMENT FOR CHRONIC EPILEPSY


AES 2021: PARTNERSHIP WITH OVID THREAPEUTICS IN EPILEPSY


CNS THERAPEUTICS XCHANGE 2021


SOCIETY FOR NEUROSCIENCE 2021


IPEG 2021. A VIRTUAL EVENT


BIOJAPAN 2021 & MORE!


SYNAPCELL IS OFF TO CALIFORNIA FOR A ROADSHOW!


LET'S TALK ABOUT YOUR NEXT PROJECT

Contact the team
SynapCell
Bâtiment SYNERGY
ZAC ISIPARC
38330 Saint Ismier – France
 
+33 (0) 458 171 583
 hello@synapcell.fr
Linkedin Twitter Youtube


ABOUT

 * Who we are
 * Back Translate
 * Partnering with us
 * Careers
 * Resources


BIOMARKERS

 * Why EEG Biomarkers?
 * What is cue?
 * Which biomarker for my research?


FOCUS

 * EPILEPSY

 * Epileptic disorders
 * Focal Epilepsy
 * Generalized Epilepsy
 * Essential Tremor

 * PARKINSON'S DISEASE

 * Parkinson's disease
 * Prodromal Parkinson's disease
 * Late-onset Parkinson's disease
 * L-DOPA induced Dyskinesia

 * EXPLORATORY PROGRAMS

 * TESTIMONIALS


OPEN INNOVATION

 * Open Innovation
 * Innovations Pipeline


CAPABILITIES

 * What we can do
 * FAQ

 * CONTACT

 * LEGALS

SYNAPCELL 2022 © – All Rights Reserved




Some cookies are needed for technical purposes on this website, they are
therefore exempted from consent. Others, non-mandatory, may be used for content
measurement, audience insights and product development. To learn more, visit our
Terms of Use.GoNo GoLegals